266 completed. 266 Phase 3, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 266 | Completed 266 |
| Phase 2 | 9 | Completed 9 |
Follow Psoriasis: new trials by email Literature Review of Psoriasis trials Research Report on Psoriasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of LZM012 ( Psoriasis ) LZM012 - Psoriasis | Phase 3 | Completed | Livzon Pharmaceutical Group Inc. | 244 | 2025-06-23 | 2026-08-05 |
| HPP737 in Adult Patients With Plaque Psoriasis HPP737, Placebo matching HPP737, Apremilast - Psoriasis | Phase 3 | Completed | Newsoara Biopharma Co., Ltd. | 607 | 2025-04-18 | 2026-08-03 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis Bimekizumab, Risankizumab, Placebo - Psoriatic Arthritis | Phase 3 | Completed | UCB Biopharma SRL | 553 | 2024-10-21 | 2026-09-02 |
| Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight Ixekizumab, Tirzepatide - Psoriasis, Obesity | Phase 3 | Completed | Eli Lilly and Company | 281 | 2024-09-30 | 2026-06-17 |
| Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight Ixekizumab, Tirzepatide - Psoriatic Arthritis, Obesity | Phase 3 | Completed | Eli Lilly and Company | 279 | 2024-09-24 | 2026-05-13 |
| Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis CMAB015, Secukinumab - Psoriasis | Phase 3 | Completed | Taizhou Mabtech Pharmaceutical Co.,Ltd | 336 | 2024-08-27 | 2026-05-07 |
| Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis HB0017 Q4W, HB0017 Q8W, placebo - Psoriasis | Phase 3 | Completed | Huabo Biopharm Co., Ltd. | 408 | 2024-03-29 | 2026-10-22 |
| A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis TAK-279 - Generalized Pustular Psoriasis, Erythrodermic Psoriasis | Phase 3 | Completed | Takeda | 18 | 2024-03-19 | 2026-07-30 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis Placebo, Bimekizumab - Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis | Phase 3 | Completed | UCB Biopharma SRL | 133 | 2023-10-31 | 2026-06-26 |
| IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment IBI112, IBI112/placebo - Psoriasis | Phase 3 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 566 | 2023-10-10 | 2025-08-17 |
| HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis. HPP737, Placebo matching HPP737 - Psoriasis | Phase 3 | Completed | Newsoara Biopharma Co., Ltd. | 515 | 2023-04-20 | 2026-08-03 |
| A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis AK111, Placebo - Psoriasis, Skin Diseases | Phase 3 | Completed | Akeso | 351 | 2023-03-31 | 2025-02-20 |
| Bioequivalence Study of Two Products of Apremilast 30 mg Tablets in Healthy, Adult, Human Subjects Apremilast 30 mg Tablets, Otezla 30 mg film-coated tablets - Psoriasis and Psoriatic Arthritis | Phase 3 | Completed | Humanis Saglık Anonim Sirketi | 36 | 2023-02-15 | 2023-12-13 |
| A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis IBI112, placebo /IBI112 - Psoriasis | Phase 3 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 500 | 2023-02-10 | 2024-10-29 |
| Roflumilast Versus Methotrexate in Psoriasis Roflumilast, Methotrexate - Psoriasis | Phase 2 / Phase 3 | Completed | Cairo University | 30 | 2023-01-09 | 2023-05-16 |
| A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis 608 Q2W, 608 Q4W, Placebo - Psoriasis | Phase 3 | Completed | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 458 | 2023-01-07 | 2025-03-11 |
| Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP 750 mg Imsidolimab, 300 mg Imsidolimab, Placebo - Generalized Pustular Psoriasis | Phase 3 | Completed | Vanda Pharmaceuticals | 45 | 2022-04-14 | 2026-03-17 |
| An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options spesolimab - Generalized Pustular Psoriasis | Phase 3 | Completed | Boehringer Ingelheim | 39 | 2022-03-15 | 2025-10-20 |
| Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP) Apremilast, Placebo - Palmoplantar Pustulosis | Phase 3 | Completed | Amgen | 176 | 2022-03-08 | 2025-04-09 |
| An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options spesolimab - Generalized Pustular Psoriasis | Phase 3 | Completed | Boehringer Ingelheim | 11 | 2022-02-17 | 2025-02-25 |
Showing 20 of 266. Sign in to see all of them.
Arthritis, Psoriatic (74) · Skin Diseases (15) · Pruritus (12) · Arthritis (11) · Lymphoma, Follicular (10) · Plaque, Amyloid (9) · Bronchiolitis Obliterans Syndrome (6) · Dermatitis (5) · Inflammation (5) · Chronic Disease (3) · Spondylarthritis (3) · Spondylarthropathies (3) · Acne Vulgaris (2) · Arthritis, Rheumatoid (2)
Skin and Connective Tissue Diseases (266) · Skin Diseases, Papulosquamous (264) · Skin Diseases (251) · Bone Diseases (74) · Spinal Diseases (74) · Spondylitis (73) · Joint Diseases (72) · Musculoskeletal Diseases (72) · Spondylarthritis (71) · Spondylarthropathies (71) · Arthritis (63) · Pathological Conditions, Signs and Symptoms (29) · Signs and Symptoms (14) · Immune System Diseases (13)
secukinumab (40) · Adalimumab (32) · Ustekinumab (22) · Etanercept (21) · apremilast (16) · risankizumab (16) · Methotrexate (15) · guselkumab (15) · bimekizumab (12) · ixekizumab (11) · tofacitinib (11) · Infliximab (10) · Certolizumab Pegol (5) · brodalumab (5) · deucravacitinib (5)
Novartis Pharmaceuticals (34) · Amgen (26) · AbbVie (19) · Eli Lilly and Company (13) · Janssen Research & Development, LLC (13) · Pfizer (12) · UCB Biopharma SRL (12) · Abbott (11) · Centocor, Inc. (7) · Bristol-Myers Squibb (6) · Merck Sharp & Dohme LLC (5) · AbbVie (prior sponsor, Abbott) (4) · Astellas Pharma Inc (4) · Boehringer Ingelheim (4) · Genentech, Inc. (4)
United States (135) · Canada (100) · Germany (99) · Poland (86) · United Kingdom (67) · Spain (64) · Hungary (62) · Russia (61) · France (58) · Czechia (57) · Australia (48) · Belgium (45) · Japan (44) · Italy (43) · Bulgaria (32)
Beverly Paperiello (3) · Victoria Butners (3) · Gilles Lauzon, PhD MD FRCPC (2)
PMID 37906417, PMID 32816215, PMID 37316690, PMID 38446397, PMID 30739254, PMID 31667790, PMID 35305260, PMID 38488975, PMID 39578348, PMID 41060492, PMID 41800601, PMID 27573260, PMID 27576559, PMID 31054118, PMID 34110605, PMID 34795065, PMID 34921669, PMID 35544084, PMID 36751950, PMID 37341961, PMID 37400681, PMID 37950894, PMID 39120848, PMID 40241921, PMID 40286813, PMID 40886218, PMID 41359217, PMID 41580158, PMID 26953848, PMID 27299809, PMID 30018799, PMID 31077258, PMID 31112005, PMID 31203228, PMID 31909868, PMID 31964419, PMID 32006348, PMID 32531798, PMID 33748660, PMID 34536218, PMID 34870800, PMID 35279805, PMID 35393269, PMID 36526796, PMID 36642439, PMID 36931693, PMID 36958766, PMID 37076998, PMID 37697121, PMID 38647975
2016 (18), 2014 (12), 2015 (9), 2018 (9), 2017 (6), 2005 (4), 2009 (4), 2023 (4), 2019 (3)